CD274 and non-small cell lung carcinoma: In a clinical trial that enrolled 563 NSCLC patients with at least 50% PD-L1 + patients, the median progression-free survival (PFS) time of the cemiplimab monotherapy group was 8.2 months, which was significantly longer than that of the chemotherapy group(Sezer et al. 2021).